Yixin Medical Completes Nearly $100 Million Series C Financing to Advance Innovative Structural Heart Therapies

Recently, MitrAssist Lifesciences in Shanghai completed nearly 100 million US dollars in Series C financing, led by existing shareholders Centurium Capital and 6 Dimensions Capital. Investors like Shanghai Jiading District State-Owned Assets Management (group) Co., Ltd., Hefei Haiheng Capital Management Co., Ltd., Hefei Industrial Investment Capital, Anhui Anyuan Investment Fund Management Co., Ltd., and Binhu Scientific City also participated in the investment.

The funds will be used to promote the research, development, and industrialization of innovative cardiovascular products in the structural heart field by MitrAssist Lifesciences.

MitrAssist Lifesciences, established in 2017, is one of the world's first cardiovascular innovative medical device companies to develop a mitral valve interventional replacement system. It aims to become an internationally leading comprehensive cardiovascular platform company. Its products mainly cover interventional heart valve treatment products (mitral valve, tricuspid valve, and aortic valve), interventional coronary drug balloon products, as well as interventional heart failure treatment products.